MX2023012457A - Compuestos para su uso en el tratamiento de trastornos hiperproliferativos. - Google Patents

Compuestos para su uso en el tratamiento de trastornos hiperproliferativos.

Info

Publication number
MX2023012457A
MX2023012457A MX2023012457A MX2023012457A MX2023012457A MX 2023012457 A MX2023012457 A MX 2023012457A MX 2023012457 A MX2023012457 A MX 2023012457A MX 2023012457 A MX2023012457 A MX 2023012457A MX 2023012457 A MX2023012457 A MX 2023012457A
Authority
MX
Mexico
Prior art keywords
treatment
hyperproliferative disorders
compounds
derivatives
hyperproliferative
Prior art date
Application number
MX2023012457A
Other languages
English (en)
Inventor
Cantador Carlos Galdeano
Alonso Xavier Barril
Palmer Héctor García
Borreil Isabel Puig
Caturla Josep Tabernero
López-Ibarra Diego Muñoz-Torrero
Carmona Sergio Ruiz
Original Assignee
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron filed Critical Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron
Publication of MX2023012457A publication Critical patent/MX2023012457A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a derivados de 2-aminotiazol o 2-aminooxazol o a una sal farmacéuticamente aceptable de los mismos para su uso en el tratamiento de trastornos hiperproliferativos, a un método de tratamiento y/o prevención de trastornos hiperproliferativos usando dichos compuestos y a un subgrupo de dichos derivados que son nuevos.
MX2023012457A 2021-04-21 2022-04-21 Compuestos para su uso en el tratamiento de trastornos hiperproliferativos. MX2023012457A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21382343.8A EP4079304A1 (en) 2021-04-21 2021-04-21 Compounds for use in the treatment of hyperproliferative disorders
PCT/EP2022/060579 WO2022223704A1 (en) 2021-04-21 2022-04-21 Compounds for use in the treatment of hyperproliferative disorders

Publications (1)

Publication Number Publication Date
MX2023012457A true MX2023012457A (es) 2023-11-22

Family

ID=75674747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012457A MX2023012457A (es) 2021-04-21 2022-04-21 Compuestos para su uso en el tratamiento de trastornos hiperproliferativos.

Country Status (11)

Country Link
US (1) US20240208998A1 (es)
EP (2) EP4079304A1 (es)
JP (1) JP2024515705A (es)
KR (1) KR20240013112A (es)
CN (1) CN117320715A (es)
AU (1) AU2022260529A1 (es)
BR (1) BR112023021959A2 (es)
CA (1) CA3216090A1 (es)
IL (1) IL307868A (es)
MX (1) MX2023012457A (es)
WO (1) WO2022223704A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002933A1 (en) * 2007-06-22 2008-12-31 Hydra Biosciences, Inc. Methods and compositions for treating disorders

Also Published As

Publication number Publication date
AU2022260529A1 (en) 2023-11-09
US20240208998A1 (en) 2024-06-27
EP4326262A1 (en) 2024-02-28
BR112023021959A2 (pt) 2023-12-26
CN117320715A (zh) 2023-12-29
CA3216090A1 (en) 2022-10-27
EP4079304A1 (en) 2022-10-26
JP2024515705A (ja) 2024-04-10
WO2022223704A1 (en) 2022-10-27
KR20240013112A (ko) 2024-01-30
IL307868A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
EP4331677A3 (en) Methods of treating feline coronavirus infections
PH12018500360A1 (en) Heteroaryl derivatives as parp inhibitors
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
PH12019550138A1 (en) Pharmaceutical combinations for treating cancer
PH12018500678A1 (en) Human plasma kallikrein inhibitors
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2021007247A (es) Derivados de rapamicina.
TN2016000489A1 (en) Carboxamide derivatives.
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MX2022003585A (es) Metodos para tratar hiperfenilalaninemia.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
PH12019501566A1 (en) Amide compounds and use thereof
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
NZ772236A (en) Pharmaceutical combination for use in age-related and/or degenerative diseases
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.